Swiss-based computational firm Genedata announces that its software system for analyzing high throughput screening data, Genedata Screener®, is in full operation at Chugai Pharmaceutical Co., Ltd. Scientists at Chugai use the system to support drug discovery efforts for disease areas such as oncology, and for diseases of the bone and joint.
During the past twelve months Genedata Screener has provided computational support throughout a complete screening cycle at Chugai. Beginning with assay optimization and followed by primary and validation screening phases, Screener has enhanced Chugai’s search for active compounds with more robust measures for biological effects within the screening cascade.
Genedata’s computational scientists in Japan, based in Tokyo, have integrated Genedata Screener® with research infrastructure at Chugai. It has been connected to Chugai’s screening platforms and result databases, providing data quality assurance and automating the analysis process from the plate readers all the way to the corporate databases.
Chugai’s screening experts use the AssayAnalyzer module to gain an overview of data quality for entire screening campaigns. Genedata’s Condoseo module is used to estimate the potency of compounds screened at multiple concentrations in the validation screening phase.
Actions speak louder than words
Genedata’s collaboration with Chugai began with a case study performed on data generated at Chugai’s research facilities in Kamkura, near Tokyo. Genedata analyzed a complete data set composed of primary and validation screening data, and presented the results to Chugai’s scientists.
The case study demonstrated the speed and efficiency of Genedata’s computational approach to screening analysis. “Data visualization and data quality assurance were key drivers behind choosing Genedata’s solution”, explained Hiroki Takaya, Group Manager, Pharmaceutical Technology Department, Chugai Pharmaceutical Co., Ltd.
This is Genedata Screener’s first collaboration in Japan. “We are strengthening our customer base internationally and our success with Chugai validates our approach to achieving close collaboration with customers on a global scale”, said Dr. Stephan Heyse, Head of Genedata Screener, Genedata AG.
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore.
Chugai Pharmaceutical specializes in prescription pharmaceuticals and based in Tokyo, is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products.
Since the start of the strategic alliance with Roche in October 2002, Chugai is actively involved in prescription pharmaceutical R&D activities in Japan and abroad as an important member of the Roche Group. Specifically, Chugai is working to develop innovative products with global applications, focusing on the disease areas of oncology, renal disease, and bone and joint.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production.
Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated sales in 2006 of Chugai was 326.1 billion yen and the operating profit was 58.3 billion yen. We are aiming at the consolidated sales 450 billion yen in 2010 that hangs in mid-term management plan "Sunrise 2010".
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.